Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 18;110(1):102-113.
doi: 10.1210/clinem/dgae431.

Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review

Affiliations
Review

Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review

Suzanne M Jan de Beur et al. J Clin Endocrinol Metab. .

Abstract

Context: Tumor-induced osteomalacia (TIO) is an ultra-rare, paraneoplastic syndrome caused by tumors that secrete fibroblast growth factor 23 (FGF23). Initial signs and musculoskeletal symptoms can be nonspecific and unrecognized, leading to long delays in diagnosis and treatment, and resulting in severe and progressive disability in patients with TIO.

Objective: This review aimed to identify published evidence on healthcare resource use in TIO to better understand the burden of the disease.

Evidence acquisition: A targeted literature review was conducted to identify publications reporting on disease characteristics and healthcare resource use associated with TIO.

Evidence synthesis: In total, 414 publications were included in the review, of which 376 were case reports. From the case reports, data on 621 patients were extracted. These patients had a mean (SD) age of 46.3 (15.8) years; 57.6% were male. Mean time from first symptoms to diagnosis of TIO was 4.6 (4.7) years and, in cases where imaging tests were reported, patients underwent a mean of 4.1 (2.7) procedures. Tumor resection was attempted in 81.0% of patients and successful in 67.0%. Fracture was reported in 49.3% of patients. Results from association analyses demonstrated that longer time to diagnosis was associated with poorer tumor resection outcomes and a higher probability of tumor recurrence. Unfavorable tumor resection outcomes were associated with greater use of pharmacologic treatment and a greater likelihood of orthopedic surgery.

Conclusion: TIO is associated with a substantial healthcare resource burden. Improvements in the diagnostic process could lead to better management of TIO, thereby benefiting patients and reducing that burden.

Keywords: clinical burden; diagnosis; healthcare resource; resection; tumor-induced osteomalacia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA diagram for the selection of eligible publications identified through MEDLINE.Abbreviations: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SLR, systematic literature review.
Figure 2.
Figure 2.
Visual representation of tumor location by anatomical region and individual site. In the case report studies, tumor locations were reported by site, which are further grouped by anatomical region here.
Figure 3.
Figure 3.
Tumor removal and recurrence. Visualization of surgical outcomes and incidence of tumor recurrence from the case report studies data.

References

    1. Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tissue Int. 2021;108(1):128‐142. - PubMed
    1. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18(3):R53‐R77. - PMC - PubMed
    1. Jan de Beur SM, Miller PD, Weber TJ, et al. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 2021;36(4):627‐635. - PMC - PubMed
    1. Jerkovich F, Nuñez S, Mocarbel Y, et al. Burden of disease in patients with tumor-induced osteomalacia. JBMR Plus. 2020;5(2):e10436. - PMC - PubMed
    1. Minisola S, Barlassina A, Vincent SA, Wood S, Williams A. A literature review to understand the burden of disease in people living with tumour-induced osteomalacia. Osteoporos Int. 2022;33(9):1845‐1857. - PMC - PubMed

MeSH terms

Substances

Supplementary concepts

Grants and funding